Safety results of a phase III trial evaluating ADT plus docetaxel versus ADT alone in hormone-naive metastatic prostate cancer patients (GETUG-AFU 15/0403)

被引：0
|
作者：
Latorzeff, I.
Esterni, B.
Habibian, M.
Delplanque, G.
Theodore, C.
Baciuchka, M.
Dauba, J.
Laguerre, B.
Krakowski, I.
Gravis, G.
机构：
[1] Clin Pasteur, Toulouse, France
[2] Inst J Paoli I Calmettes, Dept Biostat, F-13009 Marseille, France
[3] Fed Natl Ctr Lutte Canc, Paris, France
[4] Grp Hosp St Joseph, Paris, France
[5] Hop Foch, Suresnes, France
[6] Ctr Hosp Timone, Marseille, France
[7] Hop Layne, Mt De Marsan, France
[8] Ctr Eugene Marquis, Rennes, France
[9] Ctr Alexis Vautrin, Vandoeuvre Les Nancy, France
[10] INSERM, Dept Med Oncol, Inst Paoli Calmettes, UMR 891, F-13258 Marseille, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.4681
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4681
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Toxicity symptom reporting by patients and clinicians during phase III trail comparing androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in hormone-naive metastatic prostate cancer (GETUG-AFU 15/0403).
    Gravis, G.
    Fizazi, K.
    Esterni, B.
    Protiere, C.
    Habibian, M.
    Soulie, M.
    Latorzeff, I.
    Priou, F.
    Joly, F.
    Oudard, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [2] PSA response and early PSA progression evaluated in patients randomized in a phase III trial comparing androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in hormone-naive metastatic prostate cancer (GETUG-AFU 15/0403).
    Gravis, G.
    Fizazi, K.
    Joly, F.
    Oudard, S.
    Priou, F.
    Latorzeff, I.
    Delva, R.
    Esterni, B.
    Habibian, M.
    Soulie, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [3] PSA response and early PSA progression evaluated in patients randomized in a phase III trial comparing androgen-deprivation therapy (ADT) plus docetaxel versus ADT alone in hormone-naive metastatic prostate cancer (GETUG-AFU 15/0403)
    Gravis, G.
    Fizazi, K.
    Joly, F.
    Oudard, S.
    Priou, F.
    Latorzeff, I.
    Delva, R.
    Esterni, B.
    Habibian, M.
    Soulie, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [4] Androgen deprivation therapy (ADT) plus docetaxel (D) versus ADT alone for hormone-naive metastatic prostate cancer (PCa): Long-term analysis of the GETUG-AFU 15 phase III trial.
    Gravis, Gwenaelle
    Boher, Jean-Marie
    Joly, Florence
    Oudard, Stephane
    Albiges, Laurence
    Priou, Franck
    Latorzeff, Igor
    Delva, Remy
    Krakowski, Ivan
    Laguerre, Brigitte
    Rolland, Frederic
    Theodore, Christine
    Deplanque, Gael
    Ferrero, Jean-Marc
    Pouessel, Damien
    Mourey, Loic
    Beuzeboc, Philippe
    Habibian, Muriel
    Soulie, Michel
    Fizazi, Karim
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [5] SURVIVAL ANALYSIS OF A RANDOMIZED PHASE III TRIAL COMPARING ANDROGEN DEPRIVATION THERAPY (ADT) PLUS DOCETAXEL VERSUS ADT ALONE IN HORMONE-SENSITIVE METASTATIC PROSTATE CANCER (GETUG-AFU 15/0403)
    Gravis, G.
    Fizazi, K.
    Lobbedez, F. Joly
    Oudard, S.
    Priou, F.
    Latorzeff, I.
    Delva, R.
    Krakowski, I.
    Laguerre, B.
    Rolland, F.
    Theodore, C.
    Deplanque, G.
    Ferrero, J. M.
    Pouessel, D.
    Mourey, L.
    Beuzeboc, P.
    Zanetta, S.
    Esterni, B.
    Habibian, M.
    Soulie, M.
    ANNALS OF ONCOLOGY, 2012, 23 : 294 - 294
  • [6] Patients' self-assessment of tolerance and quality of life during docetaxel-based chemotherapy: Results from a phase III trial in hormone-naive metastatic prostate cancer patients (GETUG-AFU 15/0403).
    Joly, F.
    Gravis, G.
    Oudard, S.
    Soulie, M.
    Esterni, B.
    Protiere, C.
    Habibian, M.
    Latorzeff, I.
    Priou, F.
    Fizazi, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [7] Efficacy and tolerance of treatments received beyond progression in men with metastatic hormone-naive prostate cancer treated with androgen deprivation therapy (ADT) with or without docetaxel in the GETUG-AFU 15 phase III trial.
    Lavaud, Pernelle
    Gravis, Gwenaelle
    Legoupil, Clemente
    Joly, Florence
    Oudard, Stephane
    Priou, Franck
    Mourey, Loic
    Soulie, Michel
    Latorzeff, Igor
    Delva, Remy
    Krakowski, Ivan
    Laguerre, Brigitte
    Theodore, Christine
    Ferrero, Jean Marc
    Beuzeboc, Philippe
    Habibian, Muriel
    Foulon, Stephanie
    Boher, Jean Marie
    Tergemina-Clain, Gabrielle
    Fizazi, Karim
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [8] Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial
    Gravis, Gwenaelle
    Boher, Jean-Marie
    Joly, Florence
    Soulie, Michel
    Albiges, Laurence
    Priou, Franck
    Latorzeff, Igor
    Delva, Remy
    Krakowski, Ivan
    Laguerre, Brigitte
    Rolland, Frederic
    Theodore, Christine
    Deplanque, Gael
    Ferrero, Jean-Marc
    Culine, Stephane
    Mourey, Loic
    Beuzeboc, Philippe
    Habibian, Muriel
    Oudard, Stephane
    Fizazi, Karim
    EUROPEAN UROLOGY, 2016, 70 (02) : 256 - 262
  • [9] Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis
    Ayer Botrel, Tobias Engel
    Clark, Otovio
    Lima Pompeo, Antonio Carlos
    Horta Bretas, Francisco Flavio
    Sadi, Marcus Vinicius
    Ferreira, Ubirajara
    dos Reis, Rodolfo Borges
    PLOS ONE, 2016, 11 (06):
  • [10] Efficacy and Safety of Enzalutamide Plus ADT Versus Placebo Plus ADT in Metastatic Hormone-Sensitive Prostate Cancer: The Arches Trial
    Stenzl, A.
    Azad, A.
    Krivoshik, A.
    Baron, B.
    Hirmand, M.
    Armstrong, A.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 73 - 73
12345